Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.
作者： Ling Zhang , Manhua Sun , Xiaohui Zhang , Haipeng Shao
DOI:
关键词:
摘要: De novo CD5-positive diffuse large B-cell lymphoma (CD5(+) DLBCL) accounts for approximately 10% of DLBCL, and is usually associated with aggressive clinical course. We report a case CD5(+) DLBCL primary involvement the spleen liver, no distinct mass lesions or lymphadenopathy. The patient had stage IV disease bone marrow by lymphoma. cells showed characteristic portal intrasinusoidal pattern infiltrate in liver. literature was reviewed clinicopathologic features 7 similar reported cases were summarized. All share common hepatosplenomegaly without lesions, exclusive red pulp cordal spleen, poor response to conventional chemotherapy. This may represent subgroup diagnosis important prompt treatment.
参考文章(8)
A Matolcsy, D M Knowles, A Chadburn, De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. American Journal of Pathology. ,vol. 147, pp. 207- 216 ,(1995)
Rie Hyo, Naoto Tomita, Kengo Takeuchi, Tomohiro Aoshima, Atsuko Fujita, Hideyuki Kuwabara, Chizuko Hashimoto, Sachiya Takemura, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Ritsuro Suzuki, Yoshiaki Ishigatsubo, The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma Hematological Oncology. ,vol. 28, pp. 27- 32 ,(2009) , 10.1002/HON.896
Motoko Yamaguchi, Toshiyuki Ohno, Kouji Oka, Masanori Taniguchi, Motohiro Ito, Kenkichi Kita, Hiroshi Shiku, De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. British Journal of Haematology. ,vol. 105, pp. 1133- 1139 ,(1999) , 10.1046/J.1365-2141.1999.01513.X
Jason Westin, Peter McLaughlin, De novoCD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy Leukemia & Lymphoma. ,vol. 51, pp. 161- 163 ,(2010) , 10.3109/10428190903324244
D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, R. Suzuki, M. Tanimoto, K. Hatake, CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Annals of Oncology. ,vol. 19, pp. 1921- 1926 ,(2008) , 10.1093/ANNONC/MDN392
N. Niitsu, M. Okamoto, J.-i. Tamaru, T. Yoshino, N. Nakamura, S. Nakamura, K. Ohshima, H. Nakamine, M. Hirano, Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma Annals of Oncology. ,vol. 21, pp. 2069- 2074 ,(2010) , 10.1093/ANNONC/MDQ057
Motoko Yamaguchi, Masao Seto, Masataka Okamoto, Ryo Ichinohasama, Naoya Nakamura, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Takashi Akasaka, Jun-ichi Tamaru, Ritsuro Suzuki, Yoshitoyo Kagami, Masami Hirano, Yasuo Morishima, Ryuzo Ueda, Hiroshi Shiku, Shigeo Nakamura, De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood. ,vol. 99, pp. 815- 821 ,(2002) , 10.1182/BLOOD.V99.3.815
Gilles Salles, Daphne de Jong, Wanling Xie, Andreas Rosenwald, Mukesh Chhanabhai, Philippe Gaulard, Wolfram Klapper, Maria Calaminici, Birgitta Sander, Christoph Thorns, Elias Campo, Thierry Molina, Abigail Lee, Michael Pfreundschuh, Sandra Horning, Andrew Lister, Laurie H. Sehn, John Raemaekers, Anton Hagenbeek, Randy D. Gascoyne, Edie Weller, Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium Blood. ,vol. 117, pp. 7070- 7078 ,(2011) , 10.1182/BLOOD-2011-04-345256